AI Terminal
Vetoquinol SA
Report Publication Announcement • Dec 16, 2019
1747_iss_2019-12-16_97939d00-9d93-49bb-a89f-798a6b4ddaa8.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
Press Release Lure (France), December 16, 2019
2020 CALENDAR OF FINANCIAL COMMUNICATION
December 16, 2019 (Lure, France) - Vetoquinol published its calendar of financial communication for 2020.
| January 23, 2020 | 2019 Annual revenues (after market) |
|---|---|
| March 26, 2020 | 2019 Annual results (before market) |
| April 16, 2020 | 2020 First quarter revenues (after market) |
| May 26, 2020 | Annual shareholders' meeting |
| June 4, 2020 | Dividend distribution |
| July 30, 2020 | 2020 Interim revenues and interim results (after market) |
| October 15, 2020 | 2020 Third quarter revenues (after market) |
| January 21, 2021 | 2020 Annual revenues (after market) |
Next update: 2019 Annual revenues - January 23, 2020 after market close
About Vetoquinol
Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.
Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30, 2019 Vetoquinol employs 2,369 people. Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).
For further information, go to: www.vetoquinol.com.
For more information, contact: VETOQUINOL KEIMA COMMUNICATION Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 [email protected]
Investor and Media Relations Emmanuel Dovergne Tel.: +33 (0)1 56 43 44 63 [email protected]